Cytokine Pre-activation of Cryopreserved Xenogeneic-free Human Mesenchymal Stromal Cells Enhances Resolution and Repair Following Ventilator-induced Lung Injury Potentially Via a KGF-dependent Mechanism
Overview
Affiliations
Background: Human mesenchymal stem/stromal cells (hMSCs) represent a promising therapeutic strategy for ventilator-induced lung injury (VILI) and acute respiratory distress syndrome. Translational challenges include restoring hMSC efficacy following cryopreservation, developing effective xenogeneic-free (XF) hMSCs and establishing true therapeutic potential at a clinically relevant time point of administration. We wished to determine whether cytokine pre-activation of cryopreserved, bone marrow-derived XF-hMSCs would enhance their capacity to facilitate injury resolution following VILI and elucidate mechanisms of action.
Methods: Initially, in vitro studies examined the potential for the secretome from cytokine pre-activated XF-hMSCs to attenuate pulmonary epithelial injury induced by cyclic mechanical stretch. Later, anaesthetised rats underwent VILI and, 6 h following injury, were randomized to receive 1 × 10 XF-hMSC/kg that were (i) naive fresh, (ii) naive cryopreserved, (iii) cytokine pre-activated fresh or (iv) cytokine pre-activated cryopreserved, while control animals received (v) vehicle. The extent of injury resolution was measured at 24 h after injury. Finally, the role of keratinocyte growth factor (KGF) in mediating the effect of pre-activated XF-hMSCs was determined in a pulmonary epithelial wound repair model.
Results: Pre-activation enhanced the capacity of the XF-hMSC secretome to decrease stretch-induced pulmonary epithelial inflammation and injury. Both pre-activated fresh and cryopreserved XF-hMSCs enhanced resolution of injury following VILI, restoring oxygenation, improving lung compliance, reducing lung leak and improving resolution of lung structural injury. Finally, the secretome of pre-activated XF-hMSCs enhanced epithelial wound repair, in part via a KGF-dependent mechanism.
Conclusions: Cytokine pre-activation enhanced the capacity of cryopreserved, XF-hMSCs to promote injury resolution following VILI, potentially via a KGF-dependent mechanism.
Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's disease.
Ekrani S, Mahmoudi M, Haghmorad D, Kheder R, Hatami A, Esmaeili S Stem Cell Res Ther. 2024; 15(1):476.
PMID: 39696636 PMC: 11657756. DOI: 10.1186/s13287-024-04073-9.
Zhuang X, Jiang Y, Yang X, Fu L, Luo L, Dong Z Front Immunol. 2023; 14:1244930.
PMID: 37711624 PMC: 10497773. DOI: 10.3389/fimmu.2023.1244930.
Mehrabani M, Mohammadyar S, Rajizadeh M, Bejeshk M, Ahmadi B, Nematollahi M Iran J Basic Med Sci. 2023; 26(9):1001-1015.
PMID: 37605719 PMC: 10440137. DOI: 10.22038/IJBMS.2023.69023.15049.
Byrnes D, Masterson C, Brady J, Alagesan S, Gonzalez H, McCarthy S Pharmaceuticals (Basel). 2023; 16(2).
PMID: 37259300 PMC: 9961251. DOI: 10.3390/ph16020149.
Lopes-Pacheco M, Rocco P Front Pharmacol. 2023; 14:1067422.
PMID: 37007034 PMC: 10062457. DOI: 10.3389/fphar.2023.1067422.